-
-
Industry
-
-
-
-
Career Development
-
-
-
Singapore National Cancer Centre Establishes New Facilities and Research Institute to Advance Cancer Drug Development and Prevention
Published Time：
2025-10-05 15:41
Source：
Singapore, September 29, 2025 The Singapore National Cancer Centre (SNCC) has announced the establishment of new anti-cancer drug research and development facilities and a Cancer Prevention Research Institute to further support local research and innovation in cancer prevention and treatment. This initiative is expected to advance cancer drug development, early screening, and prevention efforts, bringing more precise treatment plans and higher survival rates to patients.
A key focus of the new institute is the evaluation of the "Multi-Cancer Early Detection (MCED) Test", a non-invasive blood test currently in the research phase. It is expected to provide a new reference standard for national cancer screening in the future.
The Centre also emphasized that the application of artificial intelligence (AI) in cancer treatment and drug development will be a critical driver of breakthroughs in the medical field. Through the integration of big data and AI, researchers can more efficiently explore new therapeutic pathways and enhance the development of personalized and precision medicine.
The project has received funding support from charitable foundations and various sectors of society, with the Verdant Foundation donating SGD 4.5 million specifically earmarked for the construction of new facilities and related research and development work. The Singapore National Cancer Centre plans to use this research platform to strengthen the in-depth integration of scientific research and clinical practice, promoting the implementation and popularization of new therapies.
Against the backdrop of the rapid development of the healthcare and scientific research fields, the importance of compliance and governance has become increasingly prominent. As a professional audit and advisory firm, FOZL Assurance PAC has rich experience in financial auditing, compliance supervision, risk management, and ESG consulting.
As cancer research and prevention efforts place higher demands on the transparency of fund use and the efficiency of cross-institutional collaboration, FOZL can provide medical foundations, research institutions, and relevant partners with:
Financial auditing and reporting services to ensure the rational and standardized use of research funds;
Risk and compliance management services to reduce potential risks in cross-border research and medical projects;
ESG and public welfare project evaluation services to help institutions maintain governance transparency while promoting social value.
Through these professional services, FOZL will continue to support the healthy development of the medical and scientific research industries, creating more long-term positive impacts for society.
Related News
Singapore Office：6 Raffles Quay, #14-02——#14-07, Singapore 048580
Tel：+65 6717 0088
E-mail：marketing51@fozl.sg
Follow Us
Singapore 201101725E Germany DEB8536.HRB730998 Malaysia 202201006785 (1452482-W) China